Vasculitis & polymyalgia rheumatica
Drug-induced liver injury related to avacopan therapy
Authors' conclusion
Avacopan-induced DILI is relatively common in Japan and could be lethal.
Study context
- Population
- Patients with AAV treated with avacopan at multiple centres in Japan, September 2021–March 2024
- Participants
- 22 patients
- Outcome
- DILI associated with avacopan, assessed by RECAM-J 2023
Main finding
As reported in the abstract
DILI
Avacopan
40.9%
9 of 22
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| VBDS leading to death | Avacopan 1 events |
Risk factors for severe drug-induced liver injury (DILI) with total bilirubin (T-Bil) elevation
- Older age, lower BMI and early-onset DILI after avacopan initiation
Patterns of avacopan-induced DILI
- Three patterns: short-term injury without T-Bil elevation; transient cholestatic injury with T-Bil elevation; decompensated injury with marked T-Bil elevation (vanishing bile duct syndrome (VBDS))
Safety
| Outcome | Values |
|---|---|
| Severe DILI with elevated T-Bil (among DILI cases) · a few weeks after avacopan initiationFour of the nine patients | Avacopan 44.4% |
| Improvement of DILI after discontinuation of avacopan and other medicationsEight of the nine patients | Avacopan 88.9% |
Original publication
Drug-induced liver injury related to avacopan therapy. Rheumatology (Oxford). Published 13 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →